Simplify Logo
Takeda

Takeda

Global biopharmaceutical firm; R&D-driven NMEs

Manager Global Clinical Supply Chain Planning

Full-Time
$116k - $182.3k/yr

+ Short-term and/or long-term incentives + 401(k) company match + Tuition reimbursement

Mid
Bachelor's, MBA
Lexington, MA, USA
In Person

About the job

Requirements
  • A degree in Engineering, Management, Pharmacy, or another scientific or technical field, or significant job-related experience is required.
  • At least four years of relevant pharmaceutical industry and/or contract provider experience is required.
  • The ability to communicate, organize work, collaborate with teams, and work effectively with global associates is required.
  • The ability to interact effectively with customers and suppliers, manage and resolve issues, and provide effective feedback is required.
  • The ability to handle multiple projects simultaneously while maintaining high-quality results is required.
  • The ability to recognize potential conflict and escalate when necessary is required.
  • The ability to give professional and concise presentations at internal and external meetings is required.
  • Awareness of and compliance with regulations and requirements under Good Manufacturing Practice, Good Distribution Practice, Good Clinical Practice, Annex 13, the European Union Clinical Trials Directive, and Drug Enforcement Administration or local controlled-substance regulations is required.
  • Basic understanding of GxP principles or the ability to learn key GxP methodology is required.
  • Proficiency in computer software applicable to Interactive Response Technology and Microsoft Excel is required.
  • The ability to influence stakeholders from many technical disciplines and at many levels is required.
  • The ability to apply multiple lenses to analyze and represent complex interdependencies, scenarios, and tradeoffs is required.
Responsibilities
  • Develop end-to-end supply plans for innovative medicines in clinical development.
  • Attend clinical project meetings, gather relevant information, translate clinical trial protocol information into study supply plans, forecast study product requirements, and negotiate with key project stakeholders to provide delivery timelines and budgets.
  • Maintain an enterprise view of the clinical supply chain connecting CMC, clinical operations, and commercial manufacturing perspectives across the development portfolio.
  • Perform scenario planning, make clinical supply recommendations, and mitigate risks through detailed insight into supply and demand issues for assigned clinical programs.
  • Serve as a primary interface between Clinical Operations, Pharmaceutical Sciences, Global Manufacturing and Supply, Clinical Supplies Operations, and Quality Assurance.
  • Interface with Pharmaceutical Sciences to ensure trial supplies are supported, stability programs are in progress, and appropriate expiry dating exists.
  • Work with Logistics to plan, document, and facilitate global cross-border supply strategies, including controlled-substance requirements, global trade standards, and in-country investigational-product regulatory requirements.
  • Develop operational supply plans for development products produced internally and acquired through external partnerships.
  • Oversee forecast planning and inventory management for investigational medicines and comparators across the portfolio, leading a matrix of subject-matter experts across supply chain, pharmaceutical sciences, and external partners.
  • Lead operational feasibility assessments, scenario analysis, and risk mitigation for new clinical protocols.
  • Represent the clinical supply chain to global Pharmaceutical Sciences and program teams.
  • Develop and maintain detailed clinical supply models for supply scenarios and use them as study baselines for monitoring assumptions and finished-goods inventories in ongoing clinical trials.
  • Lead the enterprise approach to supply and demand modeling, risk identification, and scenario planning for clinical supply chains.
  • Lead cross-functional planning teams in responding to unplanned events, develop supply options, facilitate decision-making, and communicate updated manufacturing and supply plans to impacted stakeholders.
  • Execute operational supply plans throughout the development lifecycle, identify leading indicators of supply risk, and escalate issues to course-correct.
  • Liaise among Clinical Operations, Pharmaceutical Sciences, and Procurement to plan and manage appropriate levels of clinical trial material and comparator supply with internal and external stakeholders.
  • Use the ClinApps Clinical Supplies Management Database to request packaging, labeling, and distribution jobs and to manage inventory and shipments.
  • Contribute to process improvements.
  • Provide input into Interactive Response Technology design for randomization and supplying drug to depots and sites.
Desired Qualifications
  • Completion of a two-year post-PharmD fellowship is preferred.
  • An MBA is preferred.
  • Experience with medical devices is a plus.
  • Experience with MS Project or equivalent project management software is a plus.

About the company

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Get referred to Takeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 FDA approval for MIMRYLO unlocks near-term U.S. oncology revenue.
  • Takeda expects ORZEYFUL U.S. launch by November 2026, pending DEA scheduling.
  • Q1 FY2026 new launches grew 22.6%, offsetting mature-brand declines and supporting guidance.

What critics are saying

  • May 18, 2026 AMITIZA verdict exposed Takeda to $2.6 billion treble-damage risk.
  • Takeda plans 4,500 FY2026 cuts, signaling launch execution pressure and organizational churn.
  • Patent erosion crushed VYVANSE sales 60.7% at constant currency in Q1 FY2026.

What makes Takeda unique

  • ORZEYFUL became the first orexin agonist approved for narcolepsy type 1 in 2026.
  • MIMRYLO offers first-in-class hepcidin mimetic therapy for polycythemia vera after FDA approval.
  • Takeda pairs global scale with Japanese discovery, including Shonan-led neurology innovation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Sep 9th, 2026
Trialbee unveils AI-powered patient screening chatbot at DPHARM 2026

Trialbee, a patient recruitment platform provider, will present at DPHARM 2026 in Boston on 15-16 September. The Swedish-American company will unveil AI-powered patient screening in its Honey Platform, enabling conversational AI chatbots to conduct initial candidate assessments whilst giving patients the option to speak with recruitment specialists. Trialbee will present jointly with pharmaceutical company Takeda on integrating their respective platforms to build research-ready patient communities that extend beyond single trials. The company will also participate in a panel discussing AI applications at clinical trial sites. The Honey Platform has added several AI features this year, including candidate summaries, duplicate detection, and recruitment data analysis. Trialbee supports over 6,000 research sites across 50 countries and reports a 91% repeat business rate with biopharmaceutical companies.

Associated Press
Sep 9th, 2026
Onco360 selected as specialty pharmacy partner for rare blood cancer drug MIMRYLO

Onco360, a US independent speciality pharmacy, has been selected by Takeda Pharmaceuticals as an ultra-narrow limited distribution partner for MIMRYLO (rusfertide). The treatment is indicated for erythrocytosis in adults with polycythemia vera. MIMRYLO is a mimetic of the endogenous hormone hepcidin that blocks the iron transporter ferroportin. This inhibition reduces iron availability for red blood cell production, resulting in lower hematocrit levels. The drug's approval was based on the phase 3 VERIFY study, a global, randomised, open-label clinical trial. The primary endpoint measured the proportion of patients achieving response during weeks 20-32, defined as the absence of phlebotomy eligibility. The most common adverse reactions were injection site reactions at 56% and anaemia at 16%.

Yahoo Finance
Aug 31st, 2026
Takeda wins FDA approval for first-in-class blood cancer drug, triggering $275M payment to Protagonist

The FDA approved Takeda Pharmaceutical's MIMRYLO (rusfertide) for polycythemia vera, a blood cancer causing red blood cell overproduction. The first-in-class drug functions as a hepcidin mimetic, regulating iron distribution to control hematocrit levels and prevent life-threatening complications like strokes and pulmonary embolisms. Approval was based on the Phase 3 VERIFY study involving 293 patients. Those receiving MIMRYLO alongside standard care achieved superior hematocrit control, reduced phlebotomy needs, and improved fatigue compared to placebo. Takeda commercialises MIMRYLO under a 2024 agreement with Protagonist Therapeutics, which discovered the drug. The approval triggers $275 million in payments to Protagonist—a $200 million opt-out fee plus $75 million milestone. Protagonist remains eligible for up to $875 million in additional milestones and tiered royalties of 14% to 29% on worldwide net sales.

Associated Press
Aug 28th, 2026
US FDA approves Takeda's Mimrylo for polycythemia vera treatment

Takeda has received US FDA approval for MIMRYLO (rusfertide), a first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV), a blood cancer. The drug is a hepcidin mimetic that regulates iron distribution and red blood cell overproduction to control hematocrit levels. The approval was supported by the Phase 3 VERIFY study involving 293 PV patients. Results showed MIMRYLO plus standard care demonstrated higher response rates than placebo, including better hematocrit control, reduced phlebotomy needs, and improved fatigue scores. PV affects approximately 90,000 people in the US. An estimated 78% of patients experience uncontrolled hematocrit with current standard care. The most common adverse events were injection site reactions and anaemia. MIMRYLO is administered once weekly via subcutaneous injection. Takeda is working with regulators outside the US for potential global availability.

Associated Press
Aug 24th, 2026
Japan approves Orzeyful as first medicine targeting narcolepsy type 1's underlying cause

Takeda announced Japan's Ministry of Health, Labour and Welfare has approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first to address the underlying orexin deficiency causing the disease, rather than just managing individual symptoms. Narcolepsy type 1 is a chronic neurological condition characterised by excessive daytime sleepiness, cataplexy, disrupted sleep, and other symptoms that significantly impact patients' daily lives. Diagnostic delays average more than 10 years. The approval follows global Phase 3 trials showing statistically significant improvements across the full range of symptoms. Common side effects included insomnia, urinary urgency and frequency, and excessive saliva. ORZEYFUL is also approved in China and the United States. Takeda developed the first-in-class orexin receptor 2 agonist in its Japanese laboratories and plans to launch the treatment quickly.